Focus: Axiom is a San Francisco-based biotechnology company specializing in AI-driven toxicity modeling for drug discovery. As a public-stage biotech, it operates across multiple therapeutic areas including neurology, ophthalmology, infectious diseases, and gastroenterology.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
7 added, 6 removed. Backfill posture.
Axiom offers innovative AI-toxicity platform exposure and diversified pipeline optionality, but severe cash constraints and minimal headcount growth create near-term career risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Axiom
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Axiom's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
fda concerns unapproved glp-1 drugs weight loss retatrutide - Philstar Life
fda concerns unapproved glp-1 drugs weight loss retatrutide Philstar Life
Axiom Space, Exobiosphere Sign Memorandum of Understanding to Advance Drug Discovery in Space - Axiom Space
Axiom Space, Exobiosphere Sign Memorandum of Understanding to Advance Drug Discovery in Space Axiom Space
Drugmakers prepare for next phase of space pharmaceuticals as ISS retirement nears - Reuters
Drugmakers prepare for next phase of space pharmaceuticals as ISS retirement nears Reuters
Axiom, GeneFab Partner to Advance Therapeutic Pipeline - Contract Pharma
Axiom, GeneFab Partner to Advance Therapeutic Pipeline Contract Pharma
Axiom Biosciences Expands Manufacturing and Clinical Development Capabilities Through Partnership with GeneFab - Yahoo Finance
Axiom Biosciences Expands Manufacturing and Clinical Development Capabilities Through Partnership with GeneFab Yahoo Finance
8-K Filing: FLEX LTD. (FLEX) (CIK 0000866374) — EX-99.1
EX-99.1
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo